A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer
Actas Urol Esp (Engl Ed). 2023 Mar;47(2):111-126.
doi: 10.1016/j.acuroe.2022.12.004.
Epub 2023 Jan 28.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Urología, Hospital Universitario Miguel Servet, Zaragoza, Spain, IIS-Aragón, Spain. Electronic address: [email protected].
- 2 Servicio de Farmacia, Hospital Universitario Virgen Macarena, Sevilla, Spain.
- 3 Servicio de Urología, Hospital Universitario Virgen de las Nieves, Granada, Spain.
- 4 Servicio de Oncología Radioterápica, Hospital Universitario Cruces, Biocruces Bizkaia Health Research Insitute, Barakaldo, Bizkaia, Spain.
- 5 Servicio de Urología, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain.
- 6 Servicio de Oncología Médica, Hospital Clínico Universitario San Carlos, Madrid, Spain.
- 7 Servicio de Urología, Hospital General Universitario de Castellón, Castellón. Spain.
- 8 Servicio de Urología, Hospital Universitario Basurto, Bilbao, Bizkaia, Spain.
- 9 Servicio de Urología Hospital Universitario Puerta del Mar., Presidente de la Asociación Española de Urología, Cádiz, Spain.
Abstract
Androgen deprivation therapy (ADT) is the mainstay treatment for metastatic hormone-sensitive prostate cancer (mHSPC). The addition of docetaxel or new hormone therapies (abiraterone, apalutamide, or enzalutamide) improves overall survival and is currently the standard of care. However, the decision on the specific regimen to accompany ADT should be discussed with the patient, considering factors such as possible associated toxicities, duration of treatment, comorbidities, patient preferences, as there is no sufficient evidence to recommend one regimen over the other in most cases. This paper summarizes the evidence on the management of mHSPC and provides consensus recommendations on the optimal treatment in combination with ADT in mHSPC patients, with special attention to the patient's clinical profile.
Keywords:
Androgen antagonists; Antagonistas de andrógenos; Clinical decision-making; Cáncer de próstata; Docetaxel; Metástasis de la neoplasia; Neoplasm metastasis; Patient preference; Patient safety; Prioridad del paciente; Prostate cancer; Seguridad del paciente; Toma de decisiones clínicas.
Copyright © 2023 AEU. Published by Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Androgen Antagonists / therapeutic use
-
Docetaxel / therapeutic use
-
Hormones / therapeutic use
-
Humans
-
Male
-
Prostatic Neoplasms* / pathology
-
Treatment Outcome
Substances
-
Androgen Antagonists
-
Docetaxel
-
Hormones